pharmaphorum

APRIL 29, 2022

An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments. DERM is being deployed in pilot studies across five NHS Trusts, for example to see if it can support GPs in referring patients to the urgent two week skin cancer referral laid out in NICE guidelines.

Hospitals 145

Hospitals 145

The Honest Apothecary

APRIL 29, 2022

Focus is the secret to improvement in any area of your life and career. What you focus on, you will get better at. Whether it be art, or sports, or business, or any other area of interest…focus makes the difference between progress and plateau. When an organization, or an individual, loses their focus, they will slowly but surely decline. No focus = no progress.

52

52

pharmaphorum

APRIL 29, 2022

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga. The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion – which is currently based across the Charles River in Boston’s Seaport District – as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpo

Vaccines 110

Vaccines 110

Pharma Times

APRIL 29, 2022

NICE urges older people to stop routine painkiller use – over 10 million in the UK suffer a form of arthritis or other joint conditions

46

46

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product – insulin icodec – which backs up earlier data suggesting it could provide effective blood glucose control when injected just once a week.

98

98

Pharma Times

APRIL 29, 2022

InRange is the first worldwide multicentre RCT to compare second generation basal insulins

48

48

pharmaphorum

APRIL 29, 2022

In the latest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Dr Colin Banas, chief medical officer at DrFirst. They discuss out of control drug pricing, especially in the United States, that has led to nonadherence and care rationing. While the world waits for systemic and policy solutions, Banas’s company is developing digital tools that can help ease the burden for patients in the meantime by getting them the lowest prices available through generics, coupons, a

52

52

pharmaphorum

APRIL 29, 2022

Bristol-Myers Squibb’s has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

FDA 52

FDA Labelling 52